Muvalaplin

Muvalaplin (LY3473329) is an orally bioavailable small molecule inhibitor of lipoprotein (a) [Lp (a) ] synthesis. It functions by disrupting the intracellular interaction between apolipoprotein (a) and apolipoprotein B-100, thereby reducing Lp (a) assembly. This mechanism supports its use in cardiovascular disease research, with studies demonstrating Lp (a) -lowering effects in both in vitro models and clinical trials.

Product Specifications

CAS Number

2565656-70-2

Product Name Alternative

LY3473329, LY-3473329, LY 3473329, Lipoprotein (a), Muvalaplin

Field of Research

Metabolism Research

Purity

97.76% (May vary between batches)

Solubility

H2O:<0.1 mg/mL; DMSO:10 mg/mL (14.07 mM)

Smiles

[C@@H] (CC1=CC (CN (CC2=CC (C[C@H] (C (O) =O) [C@]3 (CCNC3) [H]) =CC=C2) CC4=CC (C[C@H] (C (O) =O) [C@]5 (CCNC5) [H]) =CC=C4) =CC=C1) (C (O) =O) [C@]6 (CCNC6) [H]